Company intelligence / Profile preview
ImmunAbs
Seoul, Seoul Special City, South Koreaimmunabs.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ImmunAbs has successfully completed a Phase 1 clinical trial for its lead program, IM-101, a humanized monoclonal antibody targeting complement C5. The trial demonstrated good tolerability and no severe adverse events or dose-limiting toxicity. Efficacy was confirmed by biomarker analysis in healthy volunteers. The company is preparing to advance IM-101 into Phase 2 trials targeting autoimmune diseases with unmet needs.[3][6]
- Therapeutic areas
- OphthalmologyHematologyImmunologyNeurology
- Modalities
- Monoclonal antibodies (mAbs)Polyclonal antibodies (research focus)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ImmunAbs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunAbs.